Production (Stage)
ACADIA Pharmaceuticals Inc.
ACAD
$21.98
$0.432.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 22.42% | 31.85% | 47.06% | 61.65% | 56.43% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.42% | 31.85% | 47.06% | 61.65% | 56.43% |
| Cost of Revenue | -0.98% | -2.08% | -10.24% | 45.08% | 30.36% |
| Gross Profit | 45.61% | 71.89% | 137.46% | 81.27% | 95.11% |
| SG&A Expenses | 19.02% | 16.47% | 13.87% | 14.40% | 10.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.12% | 7.35% | 2.01% | 27.91% | 19.58% |
| Operating Income | 2,352.10% | 235.16% | 182.35% | 117.90% | 97.21% |
| Income Before Tax | 1,676.93% | 605.67% | 203.85% | 143.20% | 110.22% |
| Income Tax Expenses | 116.49% | 208.53% | -52.34% | 208.89% | 12,880.47% |
| Earnings from Continuing Operations | 13,484.97% | 469.50% | 186.36% | 127.58% | 98.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13,484.97% | 469.50% | 186.36% | 127.58% | 98.83% |
| EBIT | 2,352.10% | 235.16% | 182.35% | 117.90% | 97.21% |
| EBITDA | 1,820.66% | 269.64% | 192.97% | 127.58% | 103.74% |
| EPS Basic | 11,962.07% | 461.27% | 185.19% | 126.81% | 98.71% |
| Normalized Basic EPS | 1,262.50% | 320.83% | 206.73% | 136.22% | 106.39% |
| EPS Diluted | 7,291.58% | 448.69% | 183.42% | 125.14% | 97.91% |
| Normalized Diluted EPS | 1,361.70% | 318.28% | 206.07% | 135.50% | 105.93% |
| Average Basic Shares Outstanding | 1.15% | 1.24% | 1.41% | 1.51% | 1.47% |
| Average Diluted Shares Outstanding | 0.65% | 1.16% | 1.83% | 1.90% | 2.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |